Biological properties of the novel Chk1 inhibitor SAR-020106


Year:

Session type:

Paul Eve1, Mike Walton1, Angela Hayes1, Melanie Valenti1, Alexis De Haven Brandon1, Kathy Boxall1, Wynne Aherne1, Sue Eccles1, Gary Box1, Florence Raynaud1, David Williams2, Ian Collins1, John Reader2, Michelle Garrett1

1The Institute of Cancer Research, Surrey, UK, 2Sareum Ltd, Cambridge, UK

Abstract

CHK1 is a serine/threonine kinase involved in regulating cell cycle checkpoint signals that are activated in response to DNA damage and DNA errors caused by defective replication.

Share this abstractTweet about this on TwitterPrint this pageShare on FacebookEmail this to someoneShare on LinkedIn